9–12 September 2019

Congress Center Basel

Industry Session

Industry Symposia and Workshops

Visit these informative sessions to learn more about the latest scientific and technical research. 

Industry Symposia are scheduled during lunch time slots as part of the BASEL LIFE Innovation Forums programme on all 3 conference days.

Industry Presentation: Drug Development in an ever changing environment

Supported by Carbogen Amcis

Date: Tuesday, 10 September 2019
Time: 10.45 - 11.00
Room: Basel Life Stage

Speaker: Mr Volker Wolfart, Switzerland

Company presentation of a world leader in drug and pharma development focusing on speeding time to market, highly potent drugs and attractive and transparent project management for cutting edge customers worldwide. 

Industry Symposium: Life-science research in microgravity

Supported by SpacePharma S.A

Date: Tuesday, 10 September 2019
Time: 12.45 - 13.45
Room: Nairobi

Chair: Mr Martin Aebi, SpacePharma S.A, Switzerland

   Welcome - Introduction to Space 4.0
   Speaker: Mr Martin Aebi, SpacePharma S.A, Switzerland

   To infinity and beyond… the adventures of a bioengineered kidney chip onboard the International space
   Speaker: Ms Catherine Yeung, University of Washington School of Pharmacy, USA

   Microgravity effects on human serum albumin binding properties
   Speaker: Ms Alessandra Di-Masi, Roma Tre University, Italy

   Crystallization of proteins and small molecules in micro-gravity
   Speaker: Mr Guy Samburski, SpacePharma Ltd., Israel

Workshop European Job Fair: Take the Bull by the Horns: What you can do to take steps to a fulfilling career in science

Date: Tuesday, 10 September 2019
Time: 12.45 - 13.45
Room: Nairobi

Speaker: Ms Joanne Kamens, Executive Director at Addgene, Switzerland

I have a PhD, now what? How can I find out what I like? It's never too late to start thinking about career plans. This presentation is designed to inspire one to seek information and connections that will help chart a course for a happy and long-term career in science. Will address many aspects of science life including relationship building, skill building, diversity and work/life balance issues. 

Industry Workshop

Supported by SpacePharma S.A

Date: Wednesday, 11 September 2019
Time: 12.45 - 13.45
Room: Nairobi

Industry Symposium: Label-free 3D Live Cell Imaging in Drug Discovery: Introducing the CX-A, saying good bye to phototoxicity and end point assays

Supported by Nanolive

Date: Wednesday, 11 September 2019
Time: 12.45 - 13.45
Room: Samarkand

Speaker: Mr Alex Jones, Nanolive, Switzerland
Speaker: Mr Hugo Moreno, Nanolive, Switzerland

Nanolive provides high quality live cell images, label-free and in 3D, for these reasons this imaging technique is well suited for testing the effects of drugs on cell's morphological and sub-cellular organisation. To further support drug discovery applications we have developed our new automated system, the CX-A, which we are showing for the first time at MipTec / Basel Life. We will further report on recent imaging experiments where we perform a range of perturbations with various drugs in long-term time-lapse approaches. Demonstrating the practicality of the technology in a drug testing context. These experiments provide stunning video of cells evolving in a perturbed or unperturbed context. This process demonstrated that automatizing our technology should be a advantage for laboratories, both in time, cost, and the new unperturbed biological insight observed. Providing not only the possibility to evaluate drugs in prospective steps but to parallelise the process of drug effect evaluation with non-invasive, label-free power. We can now show that it is possible to use Nanolive Imaging technology for automatized drug effect evaluation in multi-well setup.


Industry Symposium: Superresolution meets High Content Screening - IXplore spinSR and scanR AI & Drug Discovery: Single Cell Injection and Extraction - Cytosurge

Supported by OLYMPUS Schweiz

Date: Wednesday, 11 September 2019
Time: 12.45 - 13.45
Room: Osaka

Chair: Ms Andrea Rackow, OLYMPUS, Germany

Superresolution meets High Content Screening - IXplore spinSR and scanR AI
   Speaker: Mr Daniel Bemmerl, OLYMPUS SOFT IMAGING SOLUTIONS GmbH, Germany

   Drug Discovery: Single Cell Injection and Extraction - Cytosurge
   Speaker: Mr Alexander Serre, CYTOSURGE AG, Switzerland

Industry Symposium: Genome Editing

Supported by Cellecta

Date: Thursday, 12 September 2019
Time: 13.15 - 14.15
Room: Samarkand


Industry Symposium: Open Science and/or Compliance – What Future do you Want for Computational Biology?

Supported by scienceindustries
Supported by Interpharma
Supported by Swiss Biotech Association 

Date: Thursday, 12 September 2019
Time: 13.15 - 14.15
Room: Sydney

Chair: Mr Markus Wyss, DSM, Switzerland
Chair: Mr Axel Braun, F. Hoffmann-La Roche Ltd, Switzerland
Chair: Mr Jan Lucht, scienceindustries, Switzerland

The Nagoya Protocol is a supplementary agreement to the Convention on Biological Diversity (CBD), and entered into force in 2014. The Nagoya Protocol is supposed to provide a transparent legal framework for the fair sharing of benefits arising out of the utilization of biological resources, thereby contributing to the conservation and sustainable use of biodiversity. It imposes obligations on all users of biological resources (both academic and industrial) to secure that access to biological resources and benefit sharing are done in full compliance with all applicable Access and Benefit Sharing (ABS) laws.

In the international negotiations around the CBD and the Nagoya Protocol, it is currently hotly debated whether also published information on biological resources (subsumed under the term “Digital Sequence Information”) should be formally included in the scope of the ABS obligations. This would have far-reaching consequences for research and innovation, and in particular for computational biology.

The ambitions of this symposium are:
   - To present the current “state of affairs”, re. the opportunities and risks of the Nagoya Protocol in
     general, and of the inclusion of “Digital Sequence Information” in the formal scope of ABS obligations
   - To provide both an academic and an industrial perspective on the potential implications for research
     and innovation
   - To trigger interest and engagement in the international debates on the future scope of ABS obligations